Clinical trial · Interventional
Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia
A Phase II, Multicenter, Open Label Study Evaluating the Efficacy and the Tolerance of Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia (MTSA)
NCT03439371CI-TRIAL-00088342MTSArecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims at evaluating the safety and the tolerance of the micro-transplantation in elderly patients with acute myeloid leukemia who are ineligible to conventional allogeneic transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HLA-mismatched micro-transplantation after induction chemotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HLA-mismatched micro-transplantation
- description
- HLA-mismatched micro-transplantation
- interventionNames
- Other: HLA-mismatched micro-transplantation after induction chemotherapy
Primary outcomes (1)
- measure
- Rate of overall survival
- timeFrame
- 2 years
- description
- Rate of overall survival will be reported.
Secondary outcomes (8)
- measure
- Hematopoietic recovery
- timeFrame
- 3 months
- description
- Number of platelets will be reported.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patient affiliated to a social security regimen or beneficiary of the same * Signed written informed consent form * Patient, ≥ 60 years-old - \< 75 years-old, with established diagnosis of de novo or secondary AML with intermediate-risk or adverse-risk cytogenetic profile, or with established myelodysplasic syndromes (RAEB), in pathologically confirmed complete remission following anti-leukemic induction therapy (\<5% blasts) * Contra-indication to conditioning regimen in conventional allogeneic transplantation Exclusion Criteria: * Patient with established diagnosis of acute myeloid leukemia with standard-risk cytogenetic profile * Promyelocytic leukemia t(15;17) * CBF-AML t(8;21) or inv(16) * Normal karyotype with a favorable molecular profile: NPM1+ and FLT3-; NPM1+, FLT3- and double mutation CEBPα or chronic myeloid leukemia in blastic phase * Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent * Refusing participation
References
Publications (0)
Data not yet available
No reference posted for this study.